CEL-SCI CORP

NYSE: CVM (Cel-Sci Corporation)

Last update: yesterday, 11:29PM

1.21

-0.26 (-17.69%)

Previous Close 1.47
Volume 879,800
Avg. Volume (3M) 218,748
Market Cap 21,282,676
Price / Book 2.22
52 Weeks Range
0.890 (-26%) — 7.80 (544%)
Earnings Date 12 Feb 2026
Diluted EPS (TTM) -1.59
Total Debt/Equity (MRQ) 72.10%
Current Ratio (MRQ) 1.48
Operating Cash Flow (TTM) -16.75 M
Levered Free Cash Flow (TTM) -8.91 M
Return on Assets (TTM) -66.82%
Return on Equity (TTM) -252.53%

AIStockmoo Score

-3.7
Earns below its cost of capital. Returns on capital falling. info
Low debt. Weak profitability. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend, but its moving averages have flattened. It is close to them. It broke below them on high volume. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net -0.25% of shares in their latest 13F filings: 22 holders increased, 8 decreased (quarter to 30 Sep 2026). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have risen every year. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near support. info
Final Score -3.67
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Cel-Sci Corporation - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
CVM 21 M - - 2.22 -3.7
CYBN 359 M - - - 0.0
NRXS 60 M - - 18.58 -1.2
NHWK 20 M - - 0.260 0.0
AEON 10 M - - - -3.3
TOVX 6 M - 0.099 0.610 -2.7

Select this tab to load the latest available analysis.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 3.71%
% Held by Institutions 14.60%

Ownership

Name Date Shares Held
Mai Capital Management 30 Sep 2026 109,280

No data within this time range.

Institutions

Institutional ownership: 12.94%

Positions Holders Shares
Increased 22 196,419
Decreased 8 208,017
New 7 29,620
Sold out 3 62,567

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

2 Positive 0 Negative 0 Neutral
Date Type Details
20 Nov 2026 Yahoo Finance CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va., November 20, 2026--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch.
10 Nov 2026 Yahoo Finance CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
VIENNA, Va., November 10, 2026--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research.
29 Oct 2026 Yahoo Finance CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were…
26 Oct 2026 Yahoo Finance CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,, October 26, 2026--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival.
15 Sep 2026 Yahoo Finance CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend, but its moving averages have flattened. It is close to them. It broke below them on high volume.
Nearest support: 1.08 – 1.40 · strong level
Nearest resistance: 1.31 – 1.65 · strong level · tested often, may give way

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria